Conclusion
We observed greater increases in EPA- and DHA-containing lipidomic species after 1 and 4 months of supplementation from a higher % rTG FO preparation (UO) containing a very similar amount of EPA and DHA, in young, normolipidemic subjects, in comparison to a lower %rTG FO preparation (Meg-3®). These data suggest that, like EE vs. rTG compositions, % rTGs in rTG FO preparations may evolve as a new chemoprofile/quality control marker that can influence its lipidomic pharmacodynamics. Given the widespread attention to fish oil supplements, and the fact that the global market value for fish oil is estimated to exceed US$23 billion [